定义狼疮患者羟氯喹安全有效的血药浓度范围:迈向精准药物监测的重要一步
该观察性研究纳入2010例接受羟氯喹血药浓度监测的系统性红斑狼疮患者,通过调整样条和逻辑回归分析确定与毒性相关的血药浓度阈值,并验证该阈值是否代表超治疗水平。结果显示血药浓度≥1150 ng/mL时毒性风险增加2.1倍且疗效饱和,慢性肾病≥3期患者超治疗浓度风险增加2.3倍。结论推荐羟氯喹治疗参考范围为750至<1150 ng/mL。
要点
- 羟氯喹血药浓度治疗参考范围为750至<1150 ng/mL。
- 血药浓度≥1150 ng/mL与毒性风险增加2.1倍及疗效饱和相关。
- 慢性肾病≥3期患者超治疗浓度风险增加2.3倍。
核心结论
- 羟氯喹血药浓度监测的治疗参考范围为750至<1150 ng/mL,可用于优化羟氯喹使用,尤其对慢性肾病≥3期患者。
研究设计与样本
- 观察性研究纳入2010例来自系统性红斑狼疮国际协作组、威斯康星、国际及法国研究并接受羟氯喹血药浓度测量的患者。
- 采用调整样条和逻辑回归分析横断面数据,先确定与羟氯喹毒性相关的血药浓度,再检验该上限阈值是否为超治疗水平(SLEDAI-2K评分≥6无进一步风险降低),最后分析慢性肾病分期与超治疗浓度的关联。
主要发现
- 在1842例患者(排除168例血药浓度极低者)中,4.9%出现羟氯喹相关毒性。
- 血药浓度≥1150 ng/mL时毒性比值比为2.1倍,累积羟氯喹剂量每增加1000 g毒性比值比为1.7倍。
- 血药浓度≥1150 ng/mL与治疗效应饱和相关,提示为超治疗水平。
- 慢性肾病≥3期患者出现超治疗水平(≥1150 ng/mL)的比值比为2.3倍。
关键数值与推荐
- 羟氯喹血药浓度治疗参考范围为750至<1150 ng/mL。
- 血药浓度≥1150 ng/mL定义为超治疗(毒性)水平。
临床怎么用
- 可考虑对系统性红斑狼疮患者进行羟氯喹血药浓度监测,以维持浓度在750至<1150 ng/mL范围内。
- 尤其应关注慢性肾病≥3期患者的羟氯喹血药浓度,其超治疗水平风险更高。
局限性
- 本研究为横断面观察性研究,未来需纵向研究验证羟氯喹血药浓度监测在优化剂量中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Using a hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust the HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring. METHODS: This observational study included patients (N = 2,010) across the Systemic Lupus International Collaborating Clinics, Wisconsin, international, and French studies who underwent HCQ blood level measurements. Using adjusted spline and logistic regression analyses on the cross-sectional data, we first identified an HCQ blood level associated with higher HCQ toxicity. Next, we tested if this upper threshold level was supratherapeutic (no further risk reduction for the Systemic Lupus Erythematosus Disease Activity Index 2000 [score ≥6]). Finally, we examined associations between chronic kidney disease (CKD) stage and supratherapeutic (toxic) HCQ blood levels. RESULTS: Among 1,842 patients (excluding 168 patients with very low HCQ blood levels), 4.9% had HCQ-related toxicity. Odds of toxicity were 2.1-fold higher with blood levels ≥1,150 ng/mL and 1.7-fold higher with the cumulative HCQ dose per 1,000-g increase. Blood levels ≥1,150 ng/mL were associated with a saturation in therapeutic effect, indicating supratherapeutic levels. Patients with CKD stage ≥3 had 2.3-fold higher odds of having supratherapeutic levels (≥1,150 ng/mL). CONCLUSION: The therapeutic reference range for HCQ blood level monitoring is 750 to <1,150 ng/mL. HCQ level monitoring could optimize HCQ use, particularly in patients with CKD stage ≥3. Future longitudinal studies are needed to validate the use of HCQ blood level monitoring in optimizing dosing.
引用
- Garg S, Blanchet B, Nguyen Y, et al. Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring. Arthritis Rheumatol. 2026. PMID: 41367131. doi:10.1002/art.70010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。